Back to Search
Start Over
Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
- Source :
- Virology
- Publication Year :
- 2021
-
Abstract
- SARS-CoV-2 is a novel coronavirus, spread among humans, and to date, more than 100 million of laboratory-confirmed cases have been reported worldwide. The virus demonstrates 96% similarity to a coronavirus from a horseshoe bat and most probably emerged from a spill over from bats or wild animal(s) to humans. Currently, two variants are circulating in the UK and South Africa and spread to many countries around the world. The impact of mutations on virus replication, virulence and transmissibility should be monitored carefully. Current data suggest recurrent infection with SARS-CoV-2 correlated to the level of neutralising antibodies and with sustained memory responses following infection. Recently, remdesivir was FDA approved for treatment of COVID-19, however many potential antivirals are currently in different clinical trials. Clinical data and experimental studies indicated that licenced vaccines are helpful in controlling the disease. However, the current vaccines should be evaluated against the emerging variants of SARS-CoV-2.
- Subjects :
- COVID-19 Vaccines
Coronavirus disease 2019 (COVID-19)
viruses
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Virulence
Disease
Biology
Viral zoonosis
medicine.disease_cause
Antiviral Agents
Viral Zoonoses
Article
Virus
03 medical and health sciences
Virology
Bats
medicine
Animals
Humans
030304 developmental biology
Coronavirus
0303 health sciences
SARS-CoV-2
030302 biochemistry & molecular biology
COVID-19
Coronavirus disease
Clinical trial
Interspecies transmission
Viral replication
2019-nCoV
Betacoronaviruses
Immunotherapy
COVID-19 vaccine
COVID-19 antivirals
Subjects
Details
- ISSN :
- 10960341
- Volume :
- 558
- Database :
- OpenAIRE
- Journal :
- Virology
- Accession number :
- edsair.doi.dedup.....51935392dd0d798412991ee243941f66